{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:37:51Z","timestamp":1794411471083,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016828","name":"Stanford Genome Technology Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019941","name":"Hopkins Population Center, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002581","name":"School of Medicine, CHA University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000179","name":"Office of the Director","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI125640"],"award-info":[{"award-number":["AI125640"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI150597"],"award-info":[{"award-number":["AI150597"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA231277"],"award-info":[{"award-number":["CA231277"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD020056"],"award-info":[{"award-number":["S10OD020056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10RR027050"],"award-info":[{"award-number":["S10RR027050"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.xcrm.2022.100868","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T10:28:11Z","timestamp":1670840891000},"page":"100868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors"],"prefix":"10.1016","volume":"4","author":[{"given":"Shoiab","family":"Bukhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Henick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Lerrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniya","family":"Gartshteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khodadadi-Jamayran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Tsirigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina G.","family":"Lagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Dallos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthen","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyer A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100868_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2022.100868_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2022.100868_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2022.100868_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2022.100868_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2022.100868_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2022.100868_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100868_bib12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2022.100868_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100868_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T\u00a0cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2159-8290.CD-21-0369","article-title":"Combined inhibition of SHP2 and CXCR1\/2 promotes antitumor T-cell response in NSCLC","volume":"12","author":"Tang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100868_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri2476","article-title":"GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation","volume":"9","author":"Ho","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2022.100868_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1396","article-title":"Increased amphiregulin expression by CD4+ T\u00a0cells from individuals with asymptomatic Leishmania donovaniinfection","volume":"11","author":"Singh","year":"2022","journal-title":"Clin. Transl. Immunology"},{"key":"10.1016\/j.xcrm.2022.100868_bib18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/jpm11090827","article-title":"PTGDR2 expression in peripheral blood as a potential biomarker in adult patients with asthma","volume":"11","author":"Garc\u00eda-S\u00e1nchez","year":"2021","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.893702","article-title":"Improving glucocorticoid sensitivity of brain-homing CD4+ T helper cells by steroid hormone crosstalk","volume":"13","author":"Koetzier","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2022.100868_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109494","article-title":"Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity","volume":"36","author":"Lam","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2022.100868_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2022.100868_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.cell.2015.11.009","article-title":"Single-cell genomics unveils critical regulators of Th17 cell pathogenicity","volume":"163","author":"Gaublomme","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2022.100868_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2022.100868_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-6-17","article-title":"GM-CSF\/IL-3\/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T\u00a0cells","volume":"6","author":"Selleri","year":"2008","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s42003-022-03596-2","article-title":"Activated-memory T\u00a0cells influence na\u00efve T\u00a0cell fate: a noncytotoxic function of human CD8 T\u00a0cells","volume":"5","author":"Sasaki","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2022.100868_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0094-2021","article-title":"Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease","volume":"30","author":"Raghu","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.xcrm.2022.100868_bib27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","article-title":"Combination therapy with PD-1 or PD-L1 inhibitors for cancer","volume":"25","author":"Hayashi","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100868_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.xcrm.2022.100868_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2022.100868_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2022.100868_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100868_bib33","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100868_bib34","article-title":"Bridging the gap: connecting the mechanisms of immune-related adverse events and autoimmunity through PD-1","volume":"9","author":"Mor","year":"2021","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122004323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122004323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:54:54Z","timestamp":1762988094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122004323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2666379122004323"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100868","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100868"}}